These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34245525)

  • 1. Biologics in autoimmune bullous diseases: Current scenario.
    Bishnoi A; De D; Handa S; Mahajan R
    Indian J Dermatol Venereol Leprol; 2021; 87(5):611-620. PubMed ID: 34245525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bullous Diseases.
    Corbaux C; Joly P
    Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatment of autoimmune blistering diseases.
    Kasperkiewicz M; Schmidt E
    Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bullous autoimmune dermatoses.
    Hofmann SC; Juratli HA; Eming R
    J Dtsch Dermatol Ges; 2018 Nov; 16(11):1339-1358. PubMed ID: 30395395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in treatment-resistant autoimmune blistering skin disorders.
    Schmidt E; Bröcker EB; Goebeler M
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):56-64. PubMed ID: 18270859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases].
    Kasperkiewicz M; Zillikens D
    Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune blistering diseases: promising agents in clinical trials.
    Olbrich H; Sadik CD; Schmidt E
    Expert Opin Investig Drugs; 2023; 32(7):615-623. PubMed ID: 37526503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.
    Czernik A; Toosi S; Bystryn JC; Grando SA
    Autoimmunity; 2012 Feb; 45(1):111-8. PubMed ID: 21923613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.
    Hertl M; Zillikens D; Borradori L; Bruckner-Tuderman L; Burckhard H; Eming R; Engert A; Goebeler M; Hofmann S; Hunzelmann N; Karlhofer F; Kautz O; Lippert U; Niedermeier A; Nitschke M; Pfütze M; Reiser M; Rose C; Schmidt E; Shimanovich I; Sticherling M; Wolff-Franke S
    J Dtsch Dermatol Ges; 2008 May; 6(5):366-73. PubMed ID: 18201220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil for the management of autoimmune bullous diseases.
    Eskin-Schwartz M; David M; Mimouni D
    Immunol Allergy Clin North Am; 2012 May; 32(2):309-15, vii. PubMed ID: 22560143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapies for Autoimmune Bullous Diseases: Current Status.
    Amber KT; Maglie R; Solimani F; Eming R; Hertl M
    Drugs; 2018 Oct; 78(15):1527-1548. PubMed ID: 30238396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.
    Ishii N; Hashimoto T; Zillikens D; Ludwig RJ
    Clin Rev Allergy Immunol; 2010 Apr; 38(2-3):186-95. PubMed ID: 19557317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment.
    Di Lernia V; Casanova DM; Goldust M; Ricci C
    Dermatol Pract Concept; 2020 Jul; 10(3):e2020050. PubMed ID: 32642305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Optimizing therapy in patients with severe autoimmune blistering skin diseases].
    Schmidt E
    Hautarzt; 2009 Aug; 60(8):633-40. PubMed ID: 19536513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Update of Autoimmune Blistering Diseases.
    Kridin K; Ahn C; Huang WC; Ansari A; Sami N
    Dermatol Clin; 2019 Apr; 37(2):215-228. PubMed ID: 30850044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of bullous pemphigoid].
    Göbel M; Eming R
    Hautarzt; 2019 Apr; 70(4):236-242. PubMed ID: 30874841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies.
    Schiavo AL; Puca RV; Ruocco V; Ruocco E
    Clin Dermatol; 2010; 28(3):337-43. PubMed ID: 20541689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil for the management of autoimmune bullous diseases.
    Eskin-Schwartz M; David M; Mimouni D
    Dermatol Clin; 2011 Oct; 29(4):555-9. PubMed ID: 21924997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.
    Kurihara Y; Yamagami J; Funakoshi T; Ishii M; Miyamoto J; Fujio Y; Kakuta R; Tanikawa A; Aoyama Y; Iwatsuki K; Ishii N; Hashimoto T; Nishie W; Shimizu H; Kouyama K; Amagai M
    J Dermatol; 2019 Feb; 46(2):124-130. PubMed ID: 30585649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.